pharmapatentsblog.com rank 29 |
Number of domains linking to pharmapatentsblog.com 4 | semantic flow 4.13 |
Number of links to pharmapatentsblog.com 47 | semantic flow 4.13 |
Number of domains linked from pharmapatentsblog.com 27 | semantic flow 6.63 |
Number of links from pharmapatentsblog.com 91 | semantic flow 6.63 |
Pages with highest topical PageRank pointing to domain.
On-topic pages from domain with highest topical PageRank.
title / url | |||||||||
---|---|---|---|---|---|---|---|---|---|
Halloween - PharmaPatents https://www.pharmapatentsblog.com/tag/halloween/ | 0.28 | 1 | 61 | 18 | 3 | 3 | 0 | 0 | |
Angiomax Patents Limited To Example | PharmaPatents https://www.pharmapatentsblog.com/2017/04/18/angiomax-patents-limited-to-example/ | 0.28 | 1 | 64 | 23 | 3 | 3 | 0 | 0 | |
Searching Review Of Stays Pending CBM Proceeding | PharmaPatents https://www.pharmapatentsblog.com/2014/09/29/federal-circuit-applies-searching-review-of-s | 0.28 | 1 | 62 | 21 | 4 | 4 | 0 | 0 | |
Three Easy Solutions to the McKesson Problem | PharmaPatents https://www.pharmapatentsblog.com/2010/06/24/three-easy-solutions-to-the-mckesson-problem/ | 0.21 | 0.94 | 62 | 19 | 4 | 4 | 0 | 0 | |
Goodlatte Obviousness Type Double Patenting Statute | PharmaPatents https://www.pharmapatentsblog.com/2013/11/05/codifying-obviousness-type-double-patenting/ | 0.21 | 1 | 62 | 21 | 3 | 3 | 0 | 0 |
On-topic pages from domain with highest topical PageRank having a few outgoing links and domains.
title / url | |||||||||
---|---|---|---|---|---|---|---|---|---|
Searching Review Of Stays Pending CBM Proceeding | PharmaPatents https://www.pharmapatentsblog.com/2014/09/29/federal-circuit-applies-searching-review-of-s | 0.28 | 1 | 62 | 21 | 4 | 4 | 0 | 0 | |
Three Easy Solutions to the McKesson Problem | PharmaPatents https://www.pharmapatentsblog.com/2010/06/24/three-easy-solutions-to-the-mckesson-problem/ | 0.21 | 0.94 | 62 | 19 | 4 | 4 | 0 | 0 |
Relevant domains with most links to selected domain.
Relevant domains with most links from selected domain.
Pages from domain with most relevant inbound links.
url | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
https://www.pharmapatentsblog.com/2010/10/25/can-pharma-patents-benefit-from-the-peertopat | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 73 | 32 | 10 | 9 | 1 | 1 | |
https://www.pharmapatentsblog.com/tag/peer/ | 1 | 0.15 | 0.98 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
https://www.pharmapatentsblog.com/ | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 81 | 30 | 5 | 5 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/patent-term-adjustment/ | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 107 | 49 | 3 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/international-patent-practice/ | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 141 | 78 | 8 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/patent-trials/ | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 130 | 60 | 5 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/tag/review/ | 1 | 0.15 | 0.99 | 0.07 | 1 | yes | 64 | 23 | 3 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/contact/ | 1 | 0.15 | 0.96 | 0.07 | 1 | yes | 58 | 16 | 2 | 2 | 0 | 0 | |
https://www.pharmapatentsblog.com/privacy-policy/ | 1 | 0.15 | 0.96 | 0.07 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/supreme-court-decisions/ | 1 | 0.15 | 0.87 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 |
Pages from domain with most likely on-topic outgoing links.
url | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
https://www.pharmapatentsblog.com/category/international-patent-practice/ | 47 | 0.15 | 0.99 | 3.01 | 1 | yes | 141 | 78 | 8 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/infringement/ | 42 | 0.15 | 0.99 | 2.55 | 1 | yes | 157 | 62 | 4 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/patent-trials/ | 40 | 0.15 | 0.99 | 2.89 | 1 | yes | 130 | 60 | 5 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/tag/examination/ | 34 | 0.15 | 0.99 | 2.25 | 1 | yes | 127 | 57 | 3 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/2010/10/25/can-pharma-patents-benefit-from-the-peertopat | 29 | 0.15 | 0.99 | 2.07 | 1 | yes | 73 | 32 | 10 | 9 | 1 | 1 | |
https://www.pharmapatentsblog.com/category/patent-term-extension/ | 24 | 0.15 | 0.99 | 1.79 | 1 | yes | 88 | 41 | 3 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/tag/patent/ | 15 | 0.15 | 0.98 | 1.11 | 1 | yes | 99 | 56 | 3 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/patent-office-practice/ | 15 | 0.15 | 0.99 | 1.01 | 1 | yes | 116 | 54 | 6 | 3 | 0 | 0 | |
https://www.pharmapatentsblog.com/ | 10 | 0.15 | 0.99 | 0.74 | 1 | yes | 81 | 30 | 5 | 5 | 0 | 0 | |
https://www.pharmapatentsblog.com/category/patent-term-adjustment/ | 7 | 0.15 | 0.99 | 0.52 | 1 | yes | 107 | 49 | 3 | 3 | 0 | 0 |
Similar domains to domain, based on inbound linking patterns from other relevant domains. This is also known in SEO as topical co-citation.